Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | A big year for CLL: ibrutinib updates from ASH

William Wierda • 4 Dec 2018
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Rituximab
ALLIANCE A041202 ECOG-E1912

The ALLIANCE A041202 (NCT01886872) and ECOG-E1912 (NCT02048813) trials were major news in the field of chronic lymphocytic leukemia (CLL) at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. William Wierda, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses these trials, which explore the use of ibrutinib as a monotherapy or in combination regimens for elderly and young patients, respectively. Prof. Wierda reveals the superiority of ibrutinib-based therapies to all other arms, with the enhanced PFS and OS rates providing a promising update to the CLL treatment landscape.

More from William Wierda

1:12
Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL
William Wierda • 10 Jun 2023
2:08
Disease characteristics impacting treatment decisions in CLL
William Wierda • 10 Jun 2023
2:20
Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN study
William Wierda • 10 Jun 2023
1:07
The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial
William Wierda • 28 Sep 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals